Thermo Fisher Scientific launches its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel

Thermo Fisher Scientific has launched its customisable menu of twenty-two verified real-time PCR assays to identify SARS-CoV-2 mutations, Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel.

The assays allow laboratories to choose which mutations to track and facilitate surveillance of variants that cause COVID-19 infections in specific regions worldwide.

The TaqMan SARS-CoV-2 Mutation Panel is intended to detect one or several mutations in a few or hundreds of samples. This allows laboratories to meet a variety of testing needs using real-time PCR instruments that they already have.

President of genetic science business, Thermo Fisher Scientific, Mark Smedley, stated: “With an evolving virus, having up to date, reliable and accurate information is critical in fighting back. With this panel, we’re empowering researchers and clinicians by putting another tool in their hands to monitor changes in the virus so they can make informed and effective decisions for overall public health.”